IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against OvaScience, Inc. (“OvaScience” or the “Company”) (Nasdaq: OVAS). Investors who purchased shares between January 8, 2015 and March 26, 2015 inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the May 26, 2017 lead plaintiff motion deadline.
If you purchased OvaScience shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The Complaint alleges that during the Class Period, OvaScience issued false and misleading statements and/or failed to disclose that: the science behind AUGMENT, a treatment specifically designed to improve a patient’s egg health, had not been scientifically validated; that the Company was unable to achieve the purported success rates it claimed; and that at all relevant times, the Company’s profitability and prospects were false and misleading. Upon release of this news, OvaScience’s stock price dropped materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.